Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMXI-3001
- Development stage
- Preclinical
- Lead developer
- AtlasMedx
- Modality
- Small Molecules
01
Overview
AMXI-3001 is a small molecule drug candidate developed by Atlasmedx, Inc. It acts as a dual inhibitor targeting both ABL proto-oncogene 1 (ABL1) and poly (ADP-ribose) polymerase (PARP). The mechanism of action involves inhibition of ABL1 and PARP enzymes, which are implicated in cancer cell survival and DNA repair pathways. By simultaneously inhibiting these targets, AMXI-3001 is designed to disrupt tumor growth and enhance the effectiveness of anticancer therapies. The primary indication under investigation for this compound is neoplasms (cancers). As of the latest update, AMXI-3001 remains in preclinical development[1][3].
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on AMXI-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMXI-3001.